Scarica l'app Stockscreener
15.55
7.39%
-1.24
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$16.79
Aprire:
$16.35
Volume 24 ore:
2.13M
Relative Volume:
0.77
Capitalizzazione di mercato:
$2.34B
Reddito:
-
Utile/perdita netta:
$-647.68M
Rapporto P/E:
-2.7425
EPS:
-5.67
Flusso di cassa netto:
$-594.49M
1 W Prestazione:
-2.57%
1M Prestazione:
+40.47%
6M Prestazione:
+39.96%
1 anno Prestazione:
+3.46%
Intervallo 1D:
$15.33
$16.42
Intervallo di 1 settimana:
$15.05
$17.28
Portata 52W:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
15.55 | 2.34B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-06 | Iniziato | Goldman | Buy |
| 2026-01-21 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey - Sahm
Enterprise value to revenue forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs - TradingView
Biohaven announces leadership changes - Hartford Business Journal
Biohaven Announces Scientific Leadership Changes - Contract Pharma
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? - Yahoo Finance
Biohaven Announces Scientific Leadership Transitions - GuruFocus
Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer - Moomoo
Biohaven: Bruce Car, Transitioning From Chief Scientific Officer to Chief Innovation Officer Focusing on External Collaborations >BHVN - Moomoo
Biohaven Announces Leadership Changes to Accelerate CNS Drug Discovery and Innovation Through Bexorg Collaboration – Minichart - Minichart
Biohaven announces leadership changes in discovery unit - Investing.com
Biohaven announces leadership changes in discovery unit By Investing.com - Investing.com South Africa
Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head - Stock Titan
Press Release: Biohaven Announces Scientific Leadership Transitions - Moomoo
Biohaven (BHVN) Completes Enrollment in RISE3 Trial - Yahoo Finance
Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves’ Disease - Sahm
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Yahoo Finance
Janus Henderson holds 8.58M Biohaven shares (BHVN) — 5.7% stake - Stock Titan
10 Best Performing American Stocks in June 2026 - Insider Monkey
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Insider Monkey
Discipline and Rules-Based Execution in BHVN Response - Stock Traders Daily
BHVNBiohaven Ltd Latest SEC Filings - Finviz
Biohaven Shares Drop 9.8% to $14.28 - Intellectia AI
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st
J.P. Morgan Maintains Biohaven(BHVN.US) With Buy Rating - Moomoo
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out - Sahm
Biohaven completes enrollment in opakalim epilepsy trial - Investing.com
BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Nigeria
Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider
Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment - Stock Titan
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo
What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio - GuruFocus
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11 - GuruFocus
Biohaven begins phase 3 trial of BHV-1300 for Graves’ disease - Investing.com
BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Australia
BofA Securities Downgrades Biohaven(BHVN.US) to Sell Rating, Cuts Target Price to $11 - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns - Investing.com
Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3 - Stock Titan
BHVN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating - Moomoo
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):